Home / Deals / Novartis has divested its Boucherville, Canada manufacturing facility Delpharm

CG Results Healthcare has advised Novartis on the divestment of its Boucherville, Canada manufacturing facility

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech, CROs & CMOs
  • Engagement Type: Sell Side
Mar 2022
has divested its Boucherville, Canada manufacturing facility

Novartis has divested its sterile fill/finish facility located in Boucherville, Canada to Delpharm, a leading contract development and manufacturing organisation with 18 plants in France, Italy, Belgium, Canada, Poland and The Netherlands. The Boucherville plant will allow Delpharm to conduct sterile vial and ampoule manufacturing in North America.

This deal represents CG Results’ 7th deal advising Novartis over the past 2 years.

Deal Team

View all Team
Kevin Bottomley

Kevin Bottomley

Managing Director
Achim Newrzella

Achim Newrzella

Director

Sector Related Deals

View All Deals
Jul 2022
has divested its API site in Rhode Island, USA, to
Read More
Jun 2022
A Kester Capital-backed company
has received investment from
Read More
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
Read More
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Read More
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Read More
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Read More
Nov 2021
has invested in
company name confidential
Read More
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Read More
Jun 2021
has acquired a drug product manufacturing facility from
Read More